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Treponema pallidum PCR (Tp-PCR) has been noted as 
a valid method for diagnosing syphilis. We compared Tp-
PCR to a combination of darkfield microscopy (DFM), the 
reference method, and serologic testing in a cohort of 273 
patients from France and Switzerland and found the diag-
nostic accuracy of Tp-PCR was higher than that for DFM. 
Incidence of syphilis, caused by Treponema pallidum, has increased steadily worldwide since the early 2000s, 
especially in at-risk populations (1). The US Centers for 
Disease Control and Prevention (CDC) recently updated 
the definitions for confirmed cases of primary and second-
ary syphilis and now considers Treponema pallidum PCR 
(Tp-PCR) to be a valid diagnostic method along with dark-
field microscopy (DFM) (2), which is still considered the 
reference test (although it remains imperfect) (3). In diag-
nosis of sexually transmitted ulcerative disease, a positive 
DFM result confirms syphilis because other T. pallidum 
subspecies are not sexually transmitted and have a dif-
ferent geographic distribution. However, the meaning of 
a negative DFM result is more uncertain. Samples from 
up to 20% of case-patients with syphilis may show nega-
tive DFM results when the test is performed by technicians 
who are not fully trained or when it is performed in subop-
timal conditions (3). Tp-PCR is clinically useful for testing 
of ulcers or skin lesions in areas where syphilis prevalence 
is high (4), but uncertainties remain because of the vari-
ability in the reference tests used in the different diagnostic 
studies. Moreover, the risk for misclassification by DFM 
diminishes the apparent value of Tp-PCR when DFM is the 
reference test because samples from syphilis patients that 
yield a negative DFM result, but a positive Tp-PCR result, 
are currently considered false-positive.
We conducted a multicenter study in France and Swit-
zerland to evaluate the accuracy of Tp-PCR compared with 
DFM and serologic testing. To resolve the difficulty of as-
sessing a new diagnostic test against an imperfect standard, 
in addition to the standard DFM diagnostics, we used an 
enhanced definition for the diagnosis of syphilis that com-
bines clinical information with DFM, serologic testing, or 
both, to enable a fair assessment to be made of the diagnos-
tic performance of Tp-PCR. 
The Study
We conducted a multicenter, prospective, observational 
study during September 2011–September 2013 in 5 centers 
in Switzerland and France (online Technical Appendix, 
http://wwwnc.cdc.gov/EID/article/21/1/14-0790-Techapp.
pdf). All patients who had a genital, anal, or oral ulcer sug-
gestive of syphilis after having at-risk sexual intercourse 
were invited to participate in the study. We used 3 defini-
tions that would indicate a diagnosis of syphilis: 1) positive 
DFM results (5); 2) a combination of nontreponemal and/or 
treponemal tests as recommended by CDC (2) (if possible, 
samples that had negative results on a first nontreponemal 
assay underwent a second test to identify seroconversion 
[6]); and 3) an enhanced definition combining clinical in-
formation suggestive of syphilis and results from DFM and 
serologic testing. The diagnosis of syphilis was established 
by positive DFM results or negative DFM results combined 
with positive serologic tests as defined by the second defi-
nition, plus a clinical outcome and a drop in nontreponemal 
titers in response to treatment.
Clinicians collected ulcer specimens in a standardized 
manner. All samples were then sent to the bacteriology 
laboratory at the University of Geneva Hospitals, where all 
Tp-PCR testing was performed by using a previously pub-
lished protocol (7) and interpreted without knowledge of 
the patient’s clinical or serologic status.
We recruited 273 patients from the 5 centers: 140 from 
Paris, France; 59 from Lyon, France; 40 from Geneva, 
Switzerland; 17 from Lausanne, Switzerland; and 17 from 
Zurich, Switzerland. Patients had a mean age of 39.0 years 
(SD 12.2); most (252, 92.3%) were men. Mean delay from 
ulcer appearance to date of first medical visit was 20.4 days 
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DISPATCHES
(SD 33.9; n = 132). Most patients were men who have sex 
with men (n = 185 [71.4%]). Ulcer localization was genital 
(n = 148, 54.2%), anorectal (n = 98, 35.9%), or oral (n = 
27, 9.9%). HIV status was known for 226 patients (82.8%); 
53 were HIV positive, and 36 were receiving antiretroviral 
drug therapy. Nine patients received an initial HIV diagno-
sis at the time of the diagnostic work-up for syphilis.
DFM results were assessed for 170 patients (62.3%); 
32 had positive results (18.8%). Results for 43 Tp-PCR 
specimens were positive; 13 of these were from patients 
who had negative DFM results. The proportion of negative 
DFM/positive Tp-PCR results was significantly higher for 
the 2 centers where DFM was performed only occasionally 
(6/15 [40.0%]) than for centers who performed DFM more 
often (7/155 [4.5%]; p<0.001). The diagnostic performance 
of Tp-PCR against DFM was high (Table 1), and agree-
ment between the 2 tests was substantial. 
Specimens from 255 patients underwent serologic 
testing; 88 patients had positive results, and 16 patients 
had undetermined results. Results for Tp-PCR were less 
sensitive and had a lower negative predictive value when 
serologic tests results were used as reference than when 
DFM results were used as reference (Table 1). Under the 
enhanced definition, however, 16 patients who had nega-
tive DFM results were considered to have syphilis, and 
Tp-PCR provided higher specificity and positive predic-
tive value when compared with this definition than when 
compared to either DFM or serologic test results alone 
(Table 1). When DFM was assessed against Tp-PCR and 
the enhanced definition (Table 2), DFM sensitivities were 
consistently lower. Additional results are shown in the 
online Technical Appendix.
Conclusions
Our results demonstrate that Tp-PCR has a high degree 
of accuracy for the definitive diagnosis of primary syphi-
lis from lesion exudate or tissue. As expected, the clinical 
value of this test appeared sensitive to the choice of ref-
erence test but was hampered by misclassification errors 
from DFM. By definition, any discrepancy between Tp-
PCR and DFM results has been considered primarily an er-
ror in Tp-PCR. However, this assumption may not always 
be accurate. 
The reliability of DFM in our study was strongly as-
sociated with routine performance. We classified cases 
with negative DFM results, positive serologic results, and 
a clinical picture evocative of syphilis as false negatives of 
the DFM. When we used this definition as a reference, the 
diagnostic performance of Tp-PCR appeared higher, indi-
cating that Tp-PCR has a high clinical usefulness either for 
confirming or for ruling out a suspicion of syphilis.
The strengths of our study are its prospective and mul-
ticenter design and the performance of Tp-PCR in a unique 
laboratory. The study sample was also representative of 
patients who may benefit from Tp-PCR in the future. The 
main limitation was the lack of a standard protocol for se-
rologic testing, which could have affected the validity of 
some analyses. However, we attempted to minimize inter-
center variability by using a blind assessment of all sero-
logic assays by 2 experts.
Our results concur with those of Grange et al., who re-
ported that Tp-PCR provides better sensitivity/specificity 
than DFM when compared with clinical suspicion of syphi-
lis (8). Similarly, Heymans et al. estimated 87.0% sensitivity 
and 93.1% specificity of Tp-PCR compared with DFM (9).
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Table 1. Summary of the various indices of performance of Tp-PCR compared with DFM, serologic testing, or an enhanced definition 
for diagnosis of primary syphilis* 
Reference 
testing 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
 
 coefficient 
(95% CI) 
Post-test probability (95% CI) 
Likelihood ratio (95% CI) If Tp-PCR is 
positive (PPV) 
If Tp-PCR is 
negative (1  NPV) Positive Negative 
DFM,  
n = 170 
93.8%  
(79.2%–99.2%) 
90.6%  
(84.4%–94.9%) 
9.95  
(5.89–16.82) 
0.07  
(0.02–0.26) 
0.74  
(0.62–0.87) 
69.8%  
(53.9%–82.8%) 
1.6%  
(0.2%–5.6%) 
Serologic,  
n = 239 
78.5%  
(68.4%–86.5%) 
93.4%  
(88.2%–96.8%) 
11.84  
(6.44–21.77) 
0.23  
(0.16–0.35) 
0.73  
(0.64–0.82) 
87.3%  
(78.0%–93.8%) 
11.9%  
(7.3%–17.9%) 
Enhanced 
definition,  
n = 170 
87.5%  
(74.8%–95.3%) 
99.2%  
(95.5%–100.0%) 
106.75  
(15.11–753.95) 
0.13  
(0.06–0.27) 
0.90  
(0.82–0.97) 
97.7%  
(87.7%–99.9%) 
4.7%  
(1.8%–10.0%) 
*Tp-PCR, Treponema pallidum PCR; DFM, darkfield microscopy; PPV, positive predictive value; NVP, negative predictive value. 
 
 
Table 2. Summary of the various indices of  performance of DFM compared with Tp-PCR or an enhanced definition for diagnosis of 
primary syphilis* 
Reference 
testing,  
n = 170 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
 
 coefficient 
(95% CI) 
Post-test probability (95% CI) 
Likelihood ratios (95% CI) If Tp-PCR is 
positive (PPV) 
If Tp-PCR is 
negative (1  NPV) Positive Negative 
Tp-PCR  69.8%  
(53.9%–82.8%) 
98.4%  
(94.4%–99.6%) 
44.30  
(11.05–177.68) 
0.31  
(0.20–0.48) 
0.74  
(0.62–0.87) 
93.8%  
(79.2%–99.2%) 
9.4%  
(5.6%–15.4%) 
Enhanced 
definition  
66.7%  
(51.6%–79.6%) 
100.0%  
(96.9%–100.0%) 
163.33  
(10.2–2615.37) 
0.33  
(0.22–0.50) 
0.74  
(0.62–0.86) 
100.0%  
(89.3%–
100.0%) 
11.6%  
(7.3%–18.0%) 
*Tp-PCR, Treponema pallidum PCR; DFM, darkfield microscopy; PPV, positive predictive value; NVP, negative predictive value. 
 
Treponema pallidum PCR for Diagnosis of Syphilis
Currently, DFM is less often used in routine testing 
than it has been in the past (10). A survey of infectious 
diseases specialists found that 56% have systematically 
performed a rapid plasma reagin test before starting treat-
ment for syphilis (10). Only 18% repeated the test if results 
were negative (10), and just 2% applied direct syndromic 
management (11). These numbers demonstrate a lack of 
consensus in the decision-making process used by experts 
and suggest that applying the guidelines for diagnosis of 
syphilis is difficult in daily practice. Moreover, although 
serologic testing can provide a background value for the 
interpretation of future tests and the assessment of treat-
ment response, these results are often noninformative in the 
early phase of the infection, when up to 30% of tests return 
false-negative results (12).
In summary, our results confirm that using Tp-PCR 
as the reference diagnostic test for early-phase syphilis 
may be reasonable (2). Several arguments weigh in favor 
of Tp-PCR. First, Tp-PCR was more accurate than DFM 
when assessed against the enhanced definition in our 
study. Second, high-quality readings of DFM are difficult 
to obtain (3), especially when the test is not routinely per-
formed. Finally, the Tp-PCR test relies less on human ex-
pertise than DFM, which may make Tp-PCR results more 
reproducible and testing less costly if it is performed on 
a routine basis.
Acknowledgments
We thank Rosemary Sudan for editorial assistance; Gisela Ge-
taz-Jimenez and Manuela Tangomo for performing the Tp-PCR; 
Deolinda Alves, Nadia Mzoughi, and Chrystelle Chapolard for 
help with data collection; and Bernard Hirschel and Béatrice 
Ninet for their advice concerning the study design. We also 
thank Fatiha Abed, Juan Ambrosioni, Caroline Barde, Philippe 
Brossard, Alexandra Calmy, Laura Ciaffi, Basile Darbellay, 
Donato Ferrara, Telma Maria Fok Lee Da Silva, Emmanuelle 
Grau, Caroline Huber, Olivier Julen, Emmanuel Laffitte, Mar-
the Thanh Lecompte, Damjan Nikolic, Frédéric Poffet, Sandrine 
Quenan, Maral Sahil, Manuel Schibler, Florence Theintz, Béa-
trice Trigona, Diem-Lan Vu-Cantero, Nasstasja Wassilew, C. 
Chapuis-Taillard, Olivier Clerc, François-Régis Duss, Laurence 
Feldmeyer, Stefano Giulieri, Manuel Joccallaz, I. Luchsinger, 
R. Kasper, Vera König, D. Reinhardt, and M. Sigg for their vol-
untary support regarding the recruitment of patients or their help 
in study implementation.
Financial support for this study was provided by the Research 
and Development Fund of the University of Geneva Hospitals (4-
2012-II).
Dr. Gayet-Ageron is a medical doctor and researcher in the Divi-
sion of Clinical Epidemiology and Infection Control Program of 
the University of Geneva Hospitals and Faculty of Medicine, Ge-
neva, Switzerland. Her primary research interest is epidemiology 
and clinical research in the field of infectious diseases.
References
  1. Torrone EA, Bertolli J, Li J, Sweeney P, Jeffries WL, Ham DC,  
et al. Increased HIV and primary and secondary syphilis diagnoses 
among young men—United States, 2004–2008. J Acquir Immune 
Defic Syndr. 2011;58:328–35.
  2. Council of State and Territorial Epidemiologists. Update to public 
health reporting and national notification for syphilis. 2014 [cited 
2014 May 30]. http://c.ymcdn.com/sites/www.cste.org/resource/
resmgr/PS/13-ID-04.pdf
  3. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and  
interpretation of tests for syphilis. Clin Microbiol Rev. 1995;8:1–21.
  4. Gayet-Ageron A, Lautenschlager S, Ninet B, Perneger TV, 
Combescure C. Sensitivity, specificity and likelihood ratios of PCR 
in the diagnosis of syphilis: a systematic review and meta-analysis. 
Sex Transm Infect. 2013;89:251–6.
  5. Centers for Disease Control and Prevention. Case definitions for 
infectious conditions under public health surveillance. MMWR 
Recomm Rep. 1997;46:1–55.
  6. French P. Syphilis. BMJ. 2007;334:143–7.
  7. Gayet-Ageron A, Ninet B, Toutous-Trellu L, Lautenschlager S, 
Furrer H, Piguet V, et al. Assessment of a real-time PCR test to 
diagnose syphilis from diverse biological samples. Sex Transm 
Infect. 2009;85:264–9.
  8. Grange PA, Gressier L, Dion PL, Farhi D, Benhaddou N, Gerhardt P, 
et al. Evaluation of a PCR test for the detection of Treponema pallidum 
in swabs and blood. J Clin Microbiol. 2012;50:546–52.
  9. Heymans R, van der Helm JJ, de Vries HJ, Fennema HS, Coutinho RA, 
Bruisten SM. Clinical value of Treponema pallidum real-time PCR for 
diagnosis of syphilis. J Clin Microbiol. 2010;48:497–502.
10. Dowell D, Polgreen PM, Beekmann SE, Workowski KA,  
Berman SM, Peterman TA. Dilemmas in the management of 
syphilis: a survey of infectious diseases experts. Clin Infect Dis. 
2009;49:1526–9.
11. Workowski KA, Berman S; Centers for Disease Control and  
Prevention. Sexually transmitted diseases. Treatment guidelines, 
2010. MMWR Recomm Rep. 2010;59:1–110.
12. Hart G. Syphilis tests in diagnostic and therapeutic decision  
making. Ann Intern Med. 1986;104:368–76.
Address for correspondence: Angèle Gayet-Ageron, Division of Clinical 
Epidemiology, University of Geneva Hospitals, 6 rue Gabrielle Perret-
Gentil, 1211 Geneva 14, Switzerland; email: angele.gayet-ageron@hcuge.ch
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 1, January 2015 129
